You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
其士集團(00025.HK)周亦卿爭產案 報告擬援引專科醫生報告
其士集團(00025.HK)創辦人周亦卿2018年病逝,家族爆出爭產訴訟,五女周蕙蕙及六女周薇薇一方今申請向法庭呈堂新增專家報告的許可,當中包括肝膽胰外科專科醫生盧寵茂爲周亦卿進行癌症手術前取得許可的事實陳述。法官歐陽浩榮表示需時考慮,將於3個月內頒佈書面判詞。 被告方申請援引專家報告,撰寫人包括腦神經專科醫生何定國及肝膽胰外科專科醫生盧寵茂。被告方指何定國醫生的報告將支持周亦卿在中風前具備立遺囑的精神能力,並會提供當時的磁力共振掃描(MRI)作爲佐證,而盧寵茂醫生曾爲周亦卿進行癌症手術,盧在術前曾向周亦卿說明手術的目的、步驟等詳請,以取得周亦卿的手術同意書,但當時周亦卿表示他有更重要的事情(即訂立遺囑)需要先做,故他希望押後手術日期。 周亦卿生前先後訂立了4份遺囑,2015年最後一份遺囑分配其士國際逾1.89億股、即62.76%股權予五女周蕙蕙,其餘遺產分配予周亦卿的妻子及其他五名兒女。長女周莉莉2019年入稟高院控告五女周蕙蕙及六女周薇薇,質疑2015年遺囑不實無效,認爲周亦卿立遺囑時不知情或因中風而無精神行爲能力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account